Log in
Enquire now
‌

US Patent 8207114 Targeted therapeutic proteins

Patent 8207114 was granted and assigned to Biomarin Pharmaceutical on June, 2012 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Current Assignee
Biomarin Pharmaceutical
Biomarin Pharmaceutical
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
8207114
Date of Patent
June 26, 2012
Patent Application Number
12610596
Date Filed
November 2, 2009
Patent Citations Received
‌
US Patent 12064485 Disulfide bond stabilized polypeptide compositions and methods of use
0
‌
US Patent 11866742 Fusion proteins comprising enzyme replacement therapy enzymes
0
Patent Primary Examiner
‌
Daniel C Gamett
Patent abstract

Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 8207114 Targeted therapeutic proteins

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.